3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
34
Lymphoma, Non-Hodgkin
25
Lymphoma, Follicular
25
Lymphoma, Large B-Cell, Diffuse
23
Lymphoma, Mantle-Cell
16
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Large-Cell, Immunoblastic
8
Waldenstrom Macroglobulinemia
6
Lymphoma, B-Cell
5
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
2
Lymphoma, Large-Cell, Anaplastic
2
Leukemia
2
Orbital lymphoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Graft vs Host Disease
1
Interventions
Rituximab
5
fludarabine
4
Tacrolimus
4
Epoetin Alfa
4
Cyclophosphamide
4
Busulfan
4
Darbepoetin alfa
3
Alemtuzumab
3
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Thiotepa
2
Therapeutics
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Etoposide
2
Early Intervention, Educational
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
trametinib
1
tirbanibulin
1
sargramostim
1
plerixafor
1
phenethyl isothiocyanate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoproliferative Disorders
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts